NCT00883883View on ClinicalTrials.gov

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Healthy
Interventions
DRUG

Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)

DRUG

Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY